TRVI logo

TREVI THERAPEUTICS INC

TRVINASDAQ
🏆 #1974 by market capEarnings Nov 11US Equity
$14.42▲ $0.04 (+0.28%)
Market closed · at close
🔔
Track TRVI
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.3%
7d▼ 0.2%
14d▼ 3.9%
30d▼ 13.2%
ytd▲ 15.3%
1y▲ 57.4%
🏦Market Cap
$2.05B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
68
Fair

Trading Snapshot

Day Range
$14.23 – $14.70
52-Week Range
$8.24 – $20.22
Volume
$2.53B
Avg Volume
$2.21B
Shares Outstanding
142.0M
Next Earnings
Dec 6, 2026

Fundamentals Snapshot

Annual Revenue
$325M
Last Q Revenue
$75M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.34
Dividend Yield
—
Dilution (1yr)
+37.3%

Why Investors Own TRVI

  • ✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 62% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TRVI logo

TREVI THERAPEUTICS INC

TRVI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$49M▼ −4.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$42M▲ +10.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
145.5M▲ +37.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$18M▼ −$15M YoY
StockOtter · stockotter.space

About TREVI THERAPEUTICS INC

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Ratings

ⓘ
Consensus
Buy
18 analysts
Strong Buy6
Buy11
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Barron’s·2h ago

TREVI THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift TRVI price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

TREVI THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.